Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Abbreviations aHUS ALL ALS aBC AD Adj. AIH Advanced breast cancer Atopic Dermatitis Adjuvant Autoimmune hepatitis atypical Hemolytic Uremic Syndrome Acute lymphoblastic leukemia Amyotrophic lateral sclerosis HF-REF HNSCC HS ΙΑ IgAN iMN IPF AMI Acute myocardial infarction JIA AML Acute myeloid leukemia jPSA/ERA aNHL Agressive non-Hodgkin's lymphoma AS H2H Ankylosing spondylitis head-to-head study versus adalimumab LVEF mCRPC BC Breast cancer MDR C3G C3 glomerulopathy MDS CCF CINDU Congestive cardiac failure Chronic inducible urticaria MS NASH CLL CML Chronic lymphocytic leukemia Chronic myeloid leukemia nHCM nr-axSpA Chronic heart failure with reduced ejection fraction Head and neck squamous cell carcinoma Hidradenitis suppurativa Interim analysis IgA nephropathy Membranous nephropathy Idiopathic pulmonary fibrosis Juvenile idiopathic arthritis Juvenile psoriatic arthritis / enthesitis-related arthritis Left ventricular ejection fraction Metastatic castration-resistant prostate cancer Multi-drug resistant Myelodysplastic syndrome Multiple sclerosis Non-alcoholic steatohepatitis Non-obstructive hypertrophic cardiomyopathy Non-radiographic axial spondyloarthritis CRC Colorectal cancer COPD Chronic obstructive pulmonary disease NSCLC PEF Non-small cell lung cancer Preserved ejection fraction COSP Chronic ocular surface pain PedPsO Pediatric psoriasis CRSWNP Severe chronic rhinosinusitis with nasal polyps PNH CSU Chronic spontaneous urticaria PsA CVRR-Lp(a) CVRR-LDLC DME Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) Secondary prevention of cardiovascular events in patients with elevated levels of LDLC Diabetic macular edema PROS RA rMS DLBCL ESCC FL GCA GVHD HCC HD HFPEF Diffuse large B-cell lymphoma refractory Esophageal squamous-cell carcinoma Follicular lymphoma Giant cell arteritis Graft-versus-host disease Hepatocellular carcinoma Huntington's disease Chronic heart failure with preserved ejection fraction RVO Retinal vein occlusion SAA SLE SpA SPMS TNBC T1DM Type 1 Diabetes mellitus SMA Type 1 SMA Type 2/3 Paroxysmal nocturnal haemoglobinuria Psoriatic arthritis PIK3CA related overgrowth spectrum Rheumatoid arthritis Relapsing multiple sclerosis Severe aplastic anemia Systemic lupus erythematosus Spinal muscular atrophy (IV formulation) Spinal muscular atrophy (IT formulation) Spondyloarthritis Secondary progressive multiple sclerosis Triple negative breast cancer 136 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation